The courts' new approach not only puts the US biotech industry at a competitive disadvantage but also misapprehends the nature of innovation in biotech.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).
Id. at 2118.
In re Roslin Institute (Edinburgh) 750 F.3d 1333 (Fed. Cir. 2015).
Id. at 1335.
Id. at 1337.
Id. at 1337.
BRCA-1 & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics Corp., 774 F.3d 755 (Fed. Cir. 2014).
Id. at 760.
Myriad, 133 S. Ct. at 2119.
Id.
Id.
Ambry, 774 F. 3d. at 760.
Id.
Id. at 761.
D'Arcy v. Myriad Genetics Inc. [2014] FCAFC 115.
Id. at ¶215.
Id.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Royzman, I. Biotechnology patents under fire. Nat Biotechnol 33, 925–926 (2015). https://doi.org/10.1038/nbt.3334
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3334
This article is cited by
-
Myriad's impact on gene patents
Nature Biotechnology (2016)
